PK/PD of repurposed Covid-19 drugs
Table 1 summarizes the observed data of pharmacokinetics and
pharmacodynamics properties of repurposed COVID-19 drugs. The
half-maximal inhibitory concentration (IC50) parameters
obtained were treated as unbound IC50, as the
experimental conditions utilize serum free conditions for COVID-19 drugs
and this hypothesis was recently supported by Fan et al [26].
However, the in vivo plasma and lung tissue concentrations were
corrected using in silico predicted tissue protein binding and
measured plasma protein binding. The preclinical rat partition
co-efficient (Kp) values for lung tissue are compared with human
predicted Kp values as listed in Supplementary Table 2 .